twist bioscience and biotia receive u.s. fda emergency use authorization for first hybridization capture based next generation sequencing sars cov 2 assay /

Twist Bioscience Corporation (NASDAQ: TWST),a company enabling customers to succeed through its offering of tall-quality synthetic DNA using its silicon platform, and Biotia, or Inc.,a company that uses proprietary analytical software for infectious disease diagnostics, today received Emergency consume Authorization (EUA) from the U.
S. Food and Drug Administration (FDA) for the SARS-CoV-2 Next-Generation Sequencing (NGS) Assay.

Source: the-scientist.com